NEW YORK (GenomeWeb) - Veracyte today announced after the close of the market that revenues for its first quarter rose 50 percent on sales of its Afirma gene expression classifier (GEC) tests.

For the three months ended March 31, 2015, the South San Francisco, California-based molecular diagnostics company said that revenues increased to $11.2 million from $7.5 million a year ago, beating the average Wall Street expectation of $10.8 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.